DE60042941D1 - Verwendung von anti-cd3 monoklonale antikörper und il-5 zur behandlung von autoimmunkrankheiten - Google Patents

Verwendung von anti-cd3 monoklonale antikörper und il-5 zur behandlung von autoimmunkrankheiten

Info

Publication number
DE60042941D1
DE60042941D1 DE60042941T DE60042941T DE60042941D1 DE 60042941 D1 DE60042941 D1 DE 60042941D1 DE 60042941 T DE60042941 T DE 60042941T DE 60042941 T DE60042941 T DE 60042941T DE 60042941 D1 DE60042941 D1 DE 60042941D1
Authority
DE
Germany
Prior art keywords
treatment
monoclonal antibodies
autoimmune diseases
inhibiting
immune response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60042941T
Other languages
English (en)
Inventor
Xiao Yan He
Bruce Milne Hall
Suzanne Jean Hodgkinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE60042941D1 publication Critical patent/DE60042941D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2033—IL-5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Audible-Bandwidth Dynamoelectric Transducers Other Than Pickups (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
DE60042941T 1999-11-26 2000-11-24 Verwendung von anti-cd3 monoklonale antikörper und il-5 zur behandlung von autoimmunkrankheiten Expired - Lifetime DE60042941D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPQ4312A AUPQ431299A0 (en) 1999-11-26 1999-11-26 Method of inducing immune tolerance
PCT/AU2000/001441 WO2001037860A1 (en) 1999-11-26 2000-11-24 Method of inducing immune tolerance

Publications (1)

Publication Number Publication Date
DE60042941D1 true DE60042941D1 (de) 2009-10-22

Family

ID=3818454

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60042941T Expired - Lifetime DE60042941D1 (de) 1999-11-26 2000-11-24 Verwendung von anti-cd3 monoklonale antikörper und il-5 zur behandlung von autoimmunkrankheiten

Country Status (7)

Country Link
US (1) US7744863B1 (de)
EP (1) EP1379270B1 (de)
AT (1) ATE442157T1 (de)
AU (2) AUPQ431299A0 (de)
CA (1) CA2429394A1 (de)
DE (1) DE60042941D1 (de)
WO (1) WO2001037860A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2380127A (en) * 2001-09-26 2003-04-02 Isis Innovation Treatment of chronic joint inflammation
US7695723B2 (en) * 2002-12-31 2010-04-13 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
AU2004291107B2 (en) 2003-11-14 2010-09-30 Brigham And Women's Hospital, Inc. Methods of modulating immunity
WO2005110481A2 (en) 2004-05-14 2005-11-24 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
WO2006081620A1 (en) 2005-02-02 2006-08-10 Newsouth Innovations Pty Limited Cd4+ cd25+ t-cells activated to a specific antigen
RU2445975C2 (ru) 2006-03-02 2012-03-27 Алексион Фармасьютикалз, Инк. Продление срока выживаемости аллотрансплантата путем ингибирования активности комплемента
WO2008014555A1 (en) 2006-08-02 2008-02-07 Newsouth Innovations Pty Limited Method of identifying cd4+cd25+ t cells activated to an antigen which express cd8
JP2010509235A (ja) * 2006-11-03 2010-03-25 ノースウェスタン ユニバーシティ 多発性硬化症の治療
CN103038256A (zh) * 2010-04-29 2013-04-10 纳斯瓦克斯有限公司 用抗cd3免疫分子疗法治疗肝炎的方法及组合物
US9447187B2 (en) 2011-02-03 2016-09-20 Alexion Pharmaceuticals, Inc. Use of an anti-CD200 antibody for prolonging the survival of allografts
EP3033093A1 (de) 2013-08-16 2016-06-22 Alexion Pharmaceuticals, Inc. Behandlung von transplantatabstossung durch verabreichung eines komplementinhibitors an ein organ vor der transplantation
US11434291B2 (en) 2019-05-14 2022-09-06 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
WO2021252917A2 (en) 2020-06-11 2021-12-16 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
WO1998047531A2 (en) * 1997-04-21 1998-10-29 Arch Development Corporation Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy

Also Published As

Publication number Publication date
AU1506501A (en) 2001-06-04
EP1379270A1 (de) 2004-01-14
CA2429394A1 (en) 2001-05-31
ATE442157T1 (de) 2009-09-15
WO2001037860A1 (en) 2001-05-31
US7744863B1 (en) 2010-06-29
EP1379270B1 (de) 2009-09-09
AUPQ431299A0 (en) 1999-12-23
EP1379270A4 (de) 2004-01-14

Similar Documents

Publication Publication Date Title
ATE177011T1 (de) Cdw52-spezifischer antikörper zur behandlung von multipler sklerose
ATE442157T1 (de) Verwendung von anti-cd3 monoklonale antikírper und il-5 zur behandlung von autoimmunkrankheiten
LU93274I2 (fr) Elotuzumab
BRPI0413489A (pt) composições polipeptìdicas de ligação a cd20
DE69636760D1 (de) Rekombinanter anti-cd4 antikörper zur menschlichen behandlung
UA111707C2 (uk) Застосування виділеного анти-tnf-альфа антитіла людини
DK0724456T3 (da) CD40-Antistoffer
NO982062D0 (no) Humaniserte antistoff mot humant gp39, sammensetninger inneholdende dette, samt terapeutisk anvendelse derav
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
DK0552296T3 (da) Monoklonale antistoffer fra mus
DE69738692D1 (de) LO-CD2a ANTIKÖRPER UND DESSEN VERWENDUNGEN ZUR HEM
DE50015629D1 (de) Verwendung cd28 spezifischer monoklonaler antikörpsetzung zur behandlung von virusinfektionen
DE60238987D1 (de) Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper
DK0610335T3 (da) Fremgangsmåder til udformning af rekombitope peptider
ATE484294T1 (de) Anti-interleukin-9 antikörper oder anti- interleukin-9 rezeptor antikörper zur behandlung von bronchialem hyperreaktionsvermögen
ATE220331T1 (de) Cd40 bindendes protein zur stimulierung der immunantwort
ATE206621T1 (de) Il-8 antagonisten zur behandlung von asthma
DE69428272D1 (de) Lo-cd2a antikörper und dessen verwendung zur inhibition von t-zell-aktivierung und -wachstum
NO981454D0 (no) Anti-FAS-antistoffer
ATE314861T1 (de) Verwendung von antikörper gegen mag zur behandlung ischämischer schlaganfälle
ATE432080T1 (de) Lo-cd2a antikörper und deren verwendung zur hemmung der t-zellen aktivierung und proliferation
TH131300B (th) ตัวแปรอิมมูโนกลูบูลินและการใช้สิ่งนั้น

Legal Events

Date Code Title Description
8364 No opposition during term of opposition